NewAmsterdam Pharma Company N.V. Ordinary Shares Earnings Dividend
Earnings Summary
Revenue | $3.7Mn |
Net Profits | $-64.14Mn |
Net Profit Margins | -1732.91% |
NewAmsterdam Pharma Company N.V. Ordinary Shares’s revenue fell -80.67% since last year same period to $3.7Mn in the Q2 2026. On a quarterly growth basis, NewAmsterdam Pharma Company N.V. Ordinary Shares has generated 21.74% jump in its revenue since last 3-months.
NewAmsterdam Pharma Company N.V. Ordinary Shares’s net profit fell -269.36% since last year same period to $-64.14Mn in the Q2 2026. On a quarterly growth basis, NewAmsterdam Pharma Company N.V. Ordinary Shares has generated -32.4% fall in its net profits since last 3-months.
NewAmsterdam Pharma Company N.V. Ordinary Shares’s net profit margin fell -1810.65% since last year same period to -1732.91% in the Q2 2026. On a quarterly growth basis, NewAmsterdam Pharma Company N.V. Ordinary Shares has generated -8.75% fall in its net profit margins since last 3-months.
Earnings per share (EPS) Estimates
EPS Estimate Current Quarter | -0.48 |
EPS Estimate Current Year | -0.48 |
NewAmsterdam Pharma Company N.V. Ordinary Shares’s earning per share (EPS) estimates for the current quarter stand at -0.48 - a -17.07% fall from last quarter’s estimates.
NewAmsterdam Pharma Company N.V. Ordinary Shares’s earning per share (EPS) estimates for the current year stand at -0.48.
Key Ratios
Earning Per Share (EPS) | -0.52 |
NewAmsterdam Pharma Company N.V. Ordinary Shares’s earning per share (EPS) fell -300% since last year same period to -0.52 in the Q2 2026. This indicates that the NewAmsterdam Pharma Company N.V. Ordinary Shares has generated -300% annual rate of fall in its earning per share (EPS) in the last 4 quarters.
Earnings Calendar
| Earnings Date | Estimated EPS | Reported EPS | Surprise % |
|---|---|---|---|
2026-05-07 | -0.41 | -0.34 | 17.07% |
2026-08-05 | -0.48 | -0.52 | -8.33% |
